Jack Nathan Medical Corp.
JNHMF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.07 | 0.07 | 0.04 |
| FCF Yield | -71.97% | -286.27% | -77.09% | -31.66% |
| EV / EBITDA | -5.54 | -2.99 | -2.05 | -2.75 |
| Quality | ||||
| ROIC | -133.03% | -44.19% | -209.22% | -138.55% |
| Gross Margin | 84.66% | 75.62% | 76.31% | 71.84% |
| Cash Conversion Ratio | -0.85 | 0.92 | 0.29 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -17.47% | 25.70% | 59.01% | 38.64% |
| Free Cash Flow Growth | 26.04% | -122.11% | 13.24% | -304.28% |
| Safety | ||||
| Net Debt / EBITDA | 1.27 | -2.16 | -0.70 | -0.02 |
| Interest Coverage | -113.80 | 0.00 | -17.00 | -46.57 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -432.38 | -265.52 | -293.76 | -208.78 |